🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesA1C target achievement rates — looking for input

A1C target achievement rates — looking for input

SurmountFan_IN Fri, Jan 9, 2026 at 4:01 PM 30 replies 1,086 viewsPage 1 of 6
SurmountFan_IN
Member
789
3,456
May 2024
Indianapolis, IN
Jan 9, 2026 at 4:01 PM#1

A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

So the question, as narrowly as I can put it: why A1C lags the way it does, and what to look at in the meantime if you want to know sooner.

If the honest answer is that nobody knows, that is a useful answer and I would rather have it.

8 3DebRD_ATL, KristenIndy, MarkLI_maint and 5 others
Reply Quote Save Share Report
CarlaRPh_TPA
Senior Member
1,890
8,234
Jan 2024
Tampa, FL
Jan 9, 2026 at 4:12 PM#2
SurmountFan_IN said:
A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:

HOMA-IR = (fasting insulin × fasting glucose) ÷ 405

My numbers: Baseline HOMA-IR = 4.7 (insulin resistant) → Current = 1.3 (insulin sensitive)

Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.

Last edited: Jan 9, 2026 at 8:12 PM
7 2ricardo_MIA, BrianDallas92, labquiet_amy and 4 others
Reply Quote Save Share Report
MounjBrad
Member
278
890
Oct 2024
Kentucky
Jan 9, 2026 at 4:23 PM#3
CarlaRPh_TPA said:
Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking: HOMA-IR = (fasting…

Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:

TestBaselineMonth 3Month 6Month 12
Glucose (fasting)1211039387
Insulin (fasting)271797
HOMA-IR5.54.22.11.5
Uric Acid8.97.16.05.2

The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 5.5 to near 1.0 is a metabolic transformation.

6 1nick_SD_fit, ben_calgary, patPC_UT and 3 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
pat_auckland
Member
345
1,567
Jun 2024
Auckland, NZ
Jan 9, 2026 at 4:34 PM#4
SurmountFan_IN said:
A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

This matches mine closely enough to be worth saying so out loud.

5 0MeganSA_TX, LarryQC_SD, wanda_boise and 2 others
Reply Quote Save Share Report
Dr.ObesityLA
VIP Member
3,567
19,876
Dec 2023
Los Angeles, CA
Jan 9, 2026 at 5:33 PM#5

Clinical perspective, offered as context rather than as advice.

Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction than glucose or A1C.

My fasting insulin: 30 → 14 → 6 uIU/mL over 9 months. Target is <7. By the time your fasting glucose is elevated, your insulin has been elevated for YEARS trying to compensate.

Ask your doctor to include fasting insulin in your bloodwork panel. It's cheap (~$20) and incredibly informative.

4 24jason_sac26, chris_chi24, tampaLisa73 and 1 other
Reply Quote Save Share Report
1236

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register